Figure 5.

LS mean (SEM) of change in DSQ scores, EREFS, and EoEHSS grade and stage TSRs from the baseline of the randomized withdrawal study (SHP631-302) to weeks 12 (a–d) and 36 (e–h) of therapy for patients who received BOS 2.0 mg b.i.d. (BOS–BOS) or withdrew to placebo (BOS–PBO) using LOCF in a post hoc analysis.

b.i.d., twice daily; BOS, budesonide oral suspension; DSQ, Dysphagia Symptom Questionnaire; EoEHSS, Eosinophilic Esophagitis Histology Scoring System; EREFS, Eosinophilic Esophagitis Endoscopic Reference Score; LOCF, last observation carried forward; LS, least-squares; PBO, placebo; SEM, standard error of the mean; TSR, total score ratio.